 The FDA has placed a partial clinical hold on Nuvation Bio Incs NYSE: NUVB Phase 1 dose-escalation study of NUV-422 in solid tumors. The companys Phase 1 trial began enrolling patients in December 2020 and, in recent months, was exploring higher doses to define a. 